If Venkat is in India, I suspect he is meeting with his cohorts and
planning their strategy here. The best time for a startup is the beginning
of the year when the pharma conferences/meetings with hedge funds and
institutions take place.
Thus, if its going to be next year for Venkat, he has to declare his intentions
soon with VYOME's intellectual properties/ into LICH Shell.
Which would mean,change the ticker symbol by late November.
Lets see how it goes..because honestly BFRI has a similar product
in phase 2b. Their cancer drug, Amulez has a unique delivery
topical delivery system for skin cancer and if approved, for
acne too.
"Biofrontera is moving forward with several studies that could expand the Ameluz indications. The company has enrolled the first group of 126 patients in a phase IIB clinical study testing the potential use of PDT for moderate to severe acne. The company is also testing the drug with a larger dosage with "3 tubes" which would apply to larger areas of the body and extremities. Biofrontera also has an ongoing phase III trial for use of PDT on superficial basal cell carcinoma."
Biofrontera notes favorable economics for U.S. medical practitioners to recommend and utilize Ameluz PDT over cryotherapy considering more attractive insurance reimbursement under existing billing codes. There is an expectation that this indirect "incentive" to dermatologists can drive growth going forward.
BFRI has a PT of $11 and $23......SO venkat, has to get going on phase 3
soon to get into the market before BFRI.. Just the way I see it
Now or Never....
For the record I own both VYOME/LICH and BFRI
TS
